Annual report pursuant to Section 13 and 15(d)

NOTE 14: COMMITMENT AND CONTINGENCIES (Details)

v3.19.1
NOTE 14: COMMITMENT AND CONTINGENCIES (Details)
12 Months Ended
Dec. 31, 2018
Commitment 1  
Other Commitments, Description On September 1, 2016, the Company entered into an amended and restated employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary
Commitment 2  
Other Commitments, Description On September 1, 2016, the Company entered into an amended and restated employment agreement with Mr. Lekharm Changoer, its Chief Technology Officer
Commitment 3  
Other Commitments, Description On April 24, 2017 the company entered into an employment agreement with Robert Malasek, its Chief Financial Officer and Secretary
Commitment 4  
Other Commitments, Description On May 7, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into a Supply Agreement with Noramco, Inc. for the long-term purchase of pharmaceutical grade dronabinol
Commitment 5  
Other Commitments, Description On August 21, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into an agreement with Revive Therapeutics Ltd. (“Revive”) to begin selling the Company’s flagship nutraceutical product
Commitment 6  
Other Commitments, Description On September 10, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into a Letter of Intent (“LOI”) with Impression Healthcare Limited (“Impression”), Australia’s largest home dental impression company, for exclusive distribution of all AXIM® Biotech products